Chul So Moon, MD
Hematology & Oncology · Wyoming, MNNPI 1316999055
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 103 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 10.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $779 and has fallen 92.8% since, to $56 in 2024.
Across 103 payments — averaging $18.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$195
- Amgen$152
- Merck$112
- Sanofi$107
- Rigel Pharmaceuticals, Inc.$87
- Pharmacyclics LLC, An Abbvie Company$85
- plus $1K from 31 others
What the payments were for
- Food & beverage$1,945100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 7 | $195 |
| Amgen | 8 | $152 |
| Merck | 6 | $112 |
| Sanofi | 5 | $107 |
| Rigel Pharmaceuticals, Inc. | 2 | $87 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $85 |
| Novartis | 4 | $82 |
| Daiichi Sankyo Inc. | 4 | $81 |
| Coherus Oncology, Inc. | 3 | $78 |
| Seagen Inc. | 5 | $77 |
| Pfizer | 5 | $74 |
| Johnson & Johnson | 4 | $66 |
| AstraZeneca(2 entities) | 4 | $65 |
| Genentech USA, Inc. | 4 | $58 |
| Exelixis Inc. | 3 | $56 |
| Incyte Corporation | 3 | $44 |
| Puma Biotechnology, Inc. | 2 | $38 |
| Bayer | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| EMD Serono, Inc. | 2 | $33 |
| Beigene USA, Inc. | 1 | $33 |
| Bristol Myers Squibb | 2 | $32 |
| Pharmacosmos Therapeutics Inc. | 2 | $31 |
| Clovis Oncology, Inc. | 2 | $28 |
| Taiho Oncology, Inc. | 2 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $26 |
| Tactile Systems Technology Inc | 1 | $21 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Gilead | 1 | $20 |
| Deciphera Pharmaceuticals Inc. | 1 | $19 |
| Apellis Pharmaceuticals, Inc. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| AbbVie | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| GSK | 1 | $15 |
| Lilly USA, LLC | 1 | $12 |
How this compares
$1,945 in reported general payments places this provider in the 70th percentile of 193 hematology & oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 25 | $556 |
| Anastrozole | 36 | $489 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 19 | $393 |
| Tamoxifen Citrate | 14 | $381 |
| Dexamethasone | 17 | $351 |
| Prednisone | 78 | $264 |
| Levothyroxine Sodium | 11 | $79 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Wyoming
- Mark RedingMinneapolis$519K
- Shilpa GuptaMinneapolis$421K
- Sagar PatelEdina$389K
- Vicki MorrisonMinneapolis$354K
- Deepti BehlRochester$205K
- Yan JiSaint Paul$164K
- Aimee MerinoMinneapolis$161K
- Yucai WangRochester$77K
- Purvi GadaChaska$76K
- Julia BakerDuluth$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.